Phytol Derivatives as Drug Resistance Reversal Agents

Phytol was chemically transformed into fifteen semi‐synthetic derivatives, which were evaluated for their antibacterial and drug resistance reversal potential in combination with nalidixic acid against E. coli strains CA8000 and DH5α. The pivaloyl (4), 3,4,5‐trimethoxybenzoyl (9), 2,3‐dichlorobenzoyl (10), cinnamoyl (11), and aldehyde (14) derivatives of phytol ((2E,7R,11R)‐3,7,11,15‐tetramethyl‐2‐hexadecen‐1‐ol) were evaluated by using another antibiotic, tetracycline, against the MDREC‐KG4 clinical isolate of E. coli. Derivative 4 decreased the maximal inhibitory concentration (MIC) of the antibiotics by 16‐fold, while derivatives 9, 10, 11, and 14 reduced MIC values of the antibiotics up to eightfold against the E. coli strains. Derivatives 4, 9, 10, 11, and 14 inhibited the ATP‐dependent efflux pump; this was also supported by their in silico binding affinity and down‐regulation of the efflux pump gene yojI, which encodes the multidrug ATP‐binding cassette transporter protein. This study supports the possible use of phytol derivatives in the development of cost‐effective antibacterial combinations.

[1]  F. Khan,et al.  4‐Hydroxy‐α‐Tetralone and its Derivative as Drug Resistance Reversal Agents in Multi Drug Resistant Escherichia coli , 2014, Chemical biology & drug design.

[2]  V. Gupta,et al.  In vivo efficacy and synergistic interaction of 16α-hydroxycleroda-3, 13 (14) Z-dien-15, 16-olide, a clerodane diterpene from Polyalthia longifolia against methicillin-resistant Staphylococcus aureus , 2013, Applied Microbiology and Biotechnology.

[3]  S. Srivastava,et al.  Antibacterial and Synergy of Clavine Alkaloid Lysergol and its Derivatives Against Nalidixic Acid‐Resistant Escherichia coli , 2013, Chemical biology & drug design.

[4]  V. Chaturvedi,et al.  Bioenhancing and antimycobacterial agents from Ammannia multiflora. , 2012, Planta medica.

[5]  J. Thakur,et al.  Anti-tubercular agents from Ammannia baccifera (Linn.) , 2012, Medicinal Chemistry Research.

[6]  R. Rodríguez,et al.  Screening of extracts of algae from Baja California sur, Mexico as reversers of the antibiotic resistance of some pathogenic bacteria. , 2010, European review for medical and pharmacological sciences.

[7]  Anton Y Peleg,et al.  Hospital-acquired infections due to gram-negative bacteria. , 2010, The New England journal of medicine.

[8]  D. Chanda,et al.  Antitubercular potential of some semisynthetic analogues of phytol. , 2010, Bioorganic & medicinal chemistry letters.

[9]  L. Amaral,et al.  Evaluation of efflux activity of bacteria by a semi-automated fluorometric system. , 2010, Methods in molecular biology.

[10]  Rafael A. Espiritu,et al.  A bioactive sesquiterpene from Bixa orellana , 2010, Journal of Natural Medicines.

[11]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[12]  J. Molnár,et al.  Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. , 2008, International journal of antimicrobial agents.

[13]  Kate E. Jones,et al.  Global trends in emerging infectious diseases , 2008, Nature.

[14]  J. Wierzbowski,et al.  Combination drugs, an emerging option for antibacterial therapy. , 2007, Trends in biotechnology.

[15]  T. Narender,et al.  A Simple and Highly Efficient Method for the Synthesis of Chalcones by Using Borontrifluoride‐etherate. , 2007 .

[16]  J. Pagés,et al.  Antibiotic Stress, Genetic Response and Altered Permeability of E. coli , 2007, PloS one.

[17]  S. Ferdinandusse,et al.  Metabolism of phytol to phytanic acid in the mouse, and the role of PPARα in its regulation Published, JLR Papers in Press, October 2, 2006. , 2007, Journal of Lipid Research.

[18]  L. Maes,et al.  Anti-infective potential of natural products: how to develop a stronger in vitro 'proof-of-concept'. , 2006, Journal of ethnopharmacology.

[19]  Fred C Tenover,et al.  Mechanisms of antimicrobial resistance in bacteria. , 2006, The American journal of medicine.

[20]  Mark S Butler,et al.  Natural products--the future scaffolds for novel antibiotics? , 2006, Biochemical pharmacology.

[21]  P. J. Powers.  Engaged mentors offer inspiration and open doors. , 2006, American Journal of Medicine.

[22]  B. Marquez.  Bacterial efflux systems and efflux pumps inhibitors. , 2005, Biochimie.

[23]  J. Molnár,et al.  Inducement and Reversal of Tetracycline Resistance in Escherichia coli K-12 and Expression of Proton Gradient-Dependent Multidrug Efflux Pump Genes , 2005, Antimicrobial Agents and Chemotherapy.

[24]  A. Saxena,et al.  Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents. , 2005, Bioorganic & medicinal chemistry letters.

[25]  N. Koyama,et al.  Cloning, sequencing and functional expression in Escherichia coli of the gene for a P-type Na(+)-ATPase of a facultatively anaerobic alkaliphile, Exiguobacterium aurantiacum. , 2005, Biochimica et biophysica acta.

[26]  X. Wu,et al.  Chalcones: an update on cytotoxic and chemoprotective properties. , 2005, Current medicinal chemistry.

[27]  M. Boeckh,et al.  Combination antifungal therapy for invasive aspergillosis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  M. Garson,et al.  Antitubercular constituents from the hexane fraction of Morinda citrifolia Linn. (Rubiaceae) , 2002, Phytotherapy research : PTR.

[29]  G. Eliopoulos,et al.  Antimicrobial Activity of Quinupristin-Dalfopristin Combined with Other Antibiotics against Vancomycin-Resistant Enterococci , 2002, Antimicrobial Agents and Chemotherapy.

[30]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[31]  P. Bloland,et al.  Combination therapy for malaria in Africa: hype or hope? , 2000, Bulletin of the World Health Organization.

[32]  N. H. Fischer,et al.  Antimycobacterial activity of (E)-phytol and derivatives: a preliminary structure-activity study. , 1998, Planta medica.

[33]  B. Levin,et al.  Adaptation to the fitness costs of antibiotic resistance in Escherichia coli , 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[34]  H. Nikaido.  Multidrug efflux pumps of gram-negative bacteria , 1996, Journal of bacteriology.

[35]  J Davies,et al.  Inactivation of antibiotics and the dissemination of resistance genes. , 1994, Science.

[36]  R A Weinstein,et al.  Epidemiology and control of nosocomial infections in adult intensive care units. , 1991, The American journal of medicine.

[37]  J. Ruiloba.  [Antimicrobial combinations]. , 1972, Gaceta medica de Mexico.